Together, these data demonstrate that Mpzl3 inhibition is a potential therapeutic approach for treatment of obesity and related comorbid conditions, including insulin resistance, hyperlipidemia and cardiovascular dysfunction. The gene discussed is MPZL3; the disease is obesity disorder.